BIXT
Bioxytran, Inc.
Set alert
- YTD
- -72.98%
- 1 year
- -70.74%
- Open
- 0.0205
- Prev close
- 0.0202
- Mkt cap
- 2.35M
- Vol
- 43.50K
- Avg vol
- 100.02K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.0205
- High
- 0.0232
- Earnings
- Nov 2, 2023
News
1 week ago globenewswire.com
Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar
Finished inventory of both products has been manufactured; Company is finalizing go-to-market plans Boston, MA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the…
2 months ago globenewswire.com
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04,…
3 months ago globenewswire.com
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement…
5 months ago globenewswire.com
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company…
7 months ago defenseworld.net
Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a…
7 months ago globenewswire.com
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology…
8 months ago globenewswire.com
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran,…
8 months ago accessnewswire.com
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a…
8 months ago globenewswire.com
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled,…
8 months ago defenseworld.net
Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 5,695 shares, an increase of 1,798.3% from…
8 months ago defenseworld.net
Bioxytran Conference: CEO touts broad-spectrum antiviral strategy, cites strong COVID Phase II results
Bioxytran (OTCMKTS:BIXT) CEO David Platt outlined the company's focus on developing drugs based on polysaccharides-complex carbohydrates-across three areas: antiviral treatment, early-stage stroke…
9 months ago globenewswire.com
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning…
10 months ago defenseworld.net
Bioxytran (OTCMKTS:BIXT) vs. Structure Therapeutics (NASDAQ:GPCR) Head-To-Head Survey
Bioxytran (OTCMKTS:BIXT - Get Free Report) and Structure Therapeutics (NASDAQ: GPCR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies…
10 months ago globenewswire.com
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025.…
11 months ago globenewswire.com
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer's, and…
1 year ago globenewswire.com
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is…
1 year ago globenewswire.com
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is…
1 year ago globenewswire.com
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:…
1 year ago globenewswire.com
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
- First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN,…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday